Broc Shot Becomes the First Supplement to Receive the Seal of Recognition From the National Psoriasis Foundation
A Breakthrough for Psoriasis: Broc Shot Earns First-Ever NPF Supplement Seal.
What is Psoriasis-prone skin?
Currently, over 8 million Americans—about 2-3% of the global population—live with psoriasis. This lifelong inflammatory disease is not a simple skin rash. It impacts the skin, joints, and other organs, and is often misunderstood as merely a cosmetic issue. Nearly 60% of those with psoriasis-prone skin report it significantly affects their daily lives. Psoriasis is also linked to other health issues, including heart disease, metabolic syndrome, depression, and psoriatic arthritis.
While severity varies, many people experience a notable impact on their quality of life. Conventional treatments like corticosteroids or UV therapy are common but can cause side effects such as dryness, irritation, or long-term skin sensitivity. Additionally, these treatments may lose effectiveness over time and can contribute to other health concerns.
Introducing Broc Shot: Natural Supplement Powered by Sulforaphane to Calm Skin from Within
Broc Shot is a unique supplement formulated with natural sulforaphane, a compound derived from whole broccoli seed powder. Sulforaphane has been clinically studied for its ability to support cellular health 1 and help the body respond to oxidative stress 2 and inflammation 3 —key drivers of skin issues like psoriasis. In 3 distinct studies, sulforaphane was clinically demonstrated to improve psoriasis-prone skin.
What is Sulforaphane and How Sulforaphane Can Help Psoriasis-Prone Skin
Sulforaphane is a sulfur-rich phytochemical found in cruciferous vegetables with the highest levels derived from broccoli seeds. Sulforaphane has over 1000 peer reviewed studies and articles demonstrating its ability to repair and nurture our gut, detoxify the body and reduce and prevent inflammation. Sulforaphane benefits include:
- Supports Cellular Health: Sulforaphane is clinically studied to help the body respond to oxidative stress and inflammation — two root causes of psoriasis flare-ups.
- Supports Immune Balance for psoriasis-prone skin: May help slow the rapid skin cell turnover process seen in psoriasis.
- Supports Detoxification and Gut Health: Natural sulforaphane enhances the body's ability to neutralize environmental toxins and supports gut barrier integrity, which can influence skin health.
"NPF is pleased to recognize Broc Shot and its potential to support the overall health of people with psoriasis," said the National Psoriasis Foundation. "This is the first supplement to earn the NPF Seal, and Broc Shot in conjunction with proper treatment can help our community live healthier lives."
Broc Shot is a simple daily ritual—just one sachet mixed with water— delivering 12 mg of natural sulforaphane. As one of the most effective supplements for psoriasis-prone skin, Broc Shot offers a non-irritating, long-term solution backed by science. Whether you're newly exploring sulforaphane benefits or looking for gentle support to help minimize skin flare-ups, Broc Shot is a trusted option to support healthier skin from within. Broc Shot is Non-GMO certified, Vegan, pesticide-free, gluten-free, plastic-free and never stabilized.
'We are honored that the National Psoriasis Foundation has awarded Broc Shot its Seal of Recognition. Our mission is to deliver a potent, natural source of sulforaphane to support rapid and lasting improvements in skin health. This recognition affirms our commitment to providing those with psoriasis-prone skin a safe and effective solution—and it inspires us to keep innovating science-backed formulas that truly make a difference in people's lives,' said Benjamin Silver, co-founder of Broc Shot.
About Broc Shot:
Broc Shot is dedicated to providing natural, science-backed supplements that support overall health and wellness. Founded on the principles of transparency and quality, Broc Shot features natural sulforaphane derived from whole broccoli seed powder, formulated to help promote detoxification and gut health, and reduce inflammation. Committed to innovation and safety, Broc Shot is Non-GMO certified, vegan, pesticide-free, gluten-free, and plastic-free in compostable packaging. For additional information about Broc Shot, visit www.brocshot.com
About the National Psoriasis Foundation:
NPF is the leading research, advocacy, and support organization representing more than 8 million people in the U.S. and over 125 million people worldwide who live with psoriasis or psoriatic arthritis. The mission of NPF is to drive efforts to cure psoriatic disease and improve the lives of all those affected. NPF is committed to creating a world free from the burdens of psoriatic disease and immediately optimizing the health of our constituents.
1 https://pubmed.ncbi.nlm.nih.gov/35126161/
2
3
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Molina Healthcare of Illinois Invests $1.6 Million to Improve Access to Health Care
CHICAGO--(BUSINESS WIRE)-- Molina Healthcare of Illinois ('Molina'), in collaboration with The MolinaCares Accord ('MolinaCares'), is announcing over $1.6 million in support of local community organizations to improve health outcomes in Illinois. "Through our partnership with Molina, PRISM is expanding the reach of our mobile immunization program, ensuring children across Chicagoland get the vaccines and preventive care they need to stay healthy,' said Zul Kapadia, president of PRISM Health. 'Molina's support allows us to bring our mobile clinic to 40 more schools and community sites, while helping us retain the health care workers who make this work possible. We're meeting families where they are and delivering care right to their doorstep." Together with community partners, Molina is working to enhance and create programs designed to address community health needs, increase access to care, improve behavioral health and maternal health outcomes, strengthen the health care workforce, and support families in Illinois. 'Molina is dedicated to ensuring everyone, regardless of their circumstances, has access to the care and resources they need,' said Matt Wolf, plan president of Molina Healthcare of Illinois. 'These investments are designed to address health disparities by helping trusted community partners carry out their missions to improve access and health outcomes for our communities.' Access to Care In Illinois, nearly 17% of adults reported having no usual source of medical care. Furthermore, across Illinois, only 28.5% of residents received a flu shot while 21.5% of children ages 5-17 received a flu shot. Molina is committed to bridging gaps by bringing care directly to individuals who need it, helping increase vaccine rates and improve health outcomes. Through this investment, Molina is supporting a mobile health program, enhancing immunization access for both adults and children, and bringing vaccines directly to schools. Behavioral Health Illinois faces significant and persistent gaps in its behavioral health system, with nearly 40% of Illinoisans living in a designated mental health professional shortage area. To address the shortage of behavioral health care, Molina is supporting initiatives that enable uninsured and underinsured individuals to access mental health care and increase the capacity of local providers to deliver care. Maternal Health Molina is committed to improving maternal health and addressing disparities so that mothers and babies can have a healthy start. Black women are more than twice as likely to die from a pregnancy-related condition and three times more likely to die from pregnancy-related medical conditions than white women. Molina is investing in initiatives to improve maternal health outcomes by increasing access to doulas, which have been shown to lower rates of cesarean delivery, reduce the risk of preterm birth, and increase postpartum visits. Health-Related Social Needs Data shows that health-related social needs, including housing, food, transportation, and economic security play a critical role in shaping health outcomes for individuals and communities. Molina's partnerships aim to address social needs that impact health by supporting free laundry services, increasing access to food, and improving housing stability. Workforce Development Molina's partnerships aim to enhance the provider workforce in communities across Illinois by providing education and training opportunities for providers and supporting programs that are building a sustainable pipeline of physicians. Approximately 89 of Illinois' 102 counties are designated as health professional shortage areas, disproportionately impacting low-income and rural residents. About The MolinaCares Accord Established by Molina Healthcare, Inc., The MolinaCares Accord oversees a community investment platform created to improve the health and well-being of disadvantaged populations by funding meaningful, measurable, and innovative programs and solutions that improve health, life, and living in local communities. The MolinaCares Accord funds such measures through the Molina Healthcare Charitable Foundation, a 501(c)(3) established in 2020 by Molina Healthcare, Inc. About Molina Healthcare of Illinois Molina Healthcare of Illinois, Inc. provides government-funded, quality health care, serving members through Medicaid, Medicare, and Marketplace programs in Illinois. Through its locally operated health plans, Molina Healthcare, Inc., a Fortune 500 company, provides managed health care services under the Medicaid and Medicare programs, and through state insurance marketplaces. For more information about Molina Healthcare of Illinois, visit
Business Wire
an hour ago
- Business Wire
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis. Enrollment is planned to begin later this year and will include patients with and without atrial fibrillation (AFib). There is a critical need for safe, effective anticoagulants for use in ESKD patients. Tecarfarin's orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. Share Patients with severe kidney disease are already at high risk for thrombotic cardiovascular events such as myocardial infarction and stroke, along with a much greater risk of AFib and venous thromboembolism compared to subjects with normal kidney function. When ESKD patients require dialysis, their transition period comes with even greater risk of myocardial infarction, stroke, and a substantial increase in mortality. 'There is a critical need for safe, effective anticoagulants for use in ESKD patients,' said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. 'Tecarfarin's orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. This study will be an important step forward for the continued development of tecarfarin in ESKD and in other areas with real opportunities to improve patient outcomes with a potentially better vitamin K antagonist.' Currently, there is limited evidence supporting the use of anticoagulant therapy in dialysis patients. Dialysis patients are often excluded from clinical trials due to their high underlying risk profile, and studies of direct oral anticoagulants (DOACs) in this patient population have not provided clear answers. Furthermore, a recent Phase 2 trial of chronic hemodialysis patients sponsored by a global company showed no benefit from the new class of Factor XI inhibitors in maintaining vascular access graft patency. To date, no prospective studies have examined the benefit of oral anticoagulation in preventing thrombotic events at the time of dialysis initiation. 'Initiating dialysis carries substantial excess risk of cardiovascular events and mortality, and to date, this risk has not been sufficiently addressed. Tecarfarin, a next-generation Vitamin K antagonist with a unique metabolism pathway that is not significantly affected by kidney impairment, has potential promise in this area of unmet need,' said Wolfgang Winkelmayer, Professor of Medicine and Chief of Nephrology at Baylor College of Medicine in Houston, Texas. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing transformative therapeutics to address limitations of current anticoagulation therapy specifically. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for several indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of managing Vitamin K antagonists and where DOACs remain inadequate or unproven. Tecarfarin received Orphan Drug Designation (ODD) and fast-track status for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation (ESKD+AFib). The company also received ODD for the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs). The company has submitted an Orphan Drug Designation Request to the US FDA for patients with chronic kidney disease who have an implanted mechanical heart valve (and consequently require lifelong anticoagulation with a VKA) who also have genetic predisposition to impaired CYP2C9 metabolism, and resulting associated challenges with achieving reliable degrees of anticoagulation with the long-term use of warfarin. Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit and connect with us on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potentially,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding initiation of clinical trial for tecarfarin in patients with ESKD transitioning to dialysis; initiation of registration trial in patients with ESKD and AFib, developing transformative therapeutics to specifically address limitations of current anticoagulation therapy; addressing a critical current treatment gap in patients with ESKD; enrollment in the planned clinical trial beginning later this year; the planned study being an important step forward for the continued development of tecarfarin in ESKD; improving patient outcomes with a potentially better vitamin K antagonist; tecarfarin offering potential promise in patients initiating dialysis; addressing the unmet needs in anticoagulation therapy; and Cadrenal's ability to pursue business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop transformative therapeutics to specifically address limitations of current anticoagulation therapy; the ability to address a critical current treatment gap in patients with ESKD; the ability to advance an innovative solution to address the unmet needs in anticoagulation therapy; the ability to initiate and successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
New York Post
an hour ago
- New York Post
This change to your skin can be a sign you have one of the deadliest cancers
It's a lot to digest. About 67,400 Americans will be diagnosed with pancreatic cancer this year, and nearly 52,000 will die from it, according to American Cancer Society estimates. The highly aggressive disease develops from abnormal cell growth within the pancreas, a vital organ that plays a crucial role in digestion and blood sugar regulation. Advertisement 4 Dr. Diane Simeone is the founding director of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, which aims to increase the five-year pancreatic cancer survival rate from 13% to 50%. Courtesy of the PRECEDE Consortium It's one of the deadliest cancers — only 13% of pancreatic cancer patients typically survive five years after diagnosis — because early detection is so difficult. 'The pancreas is hidden deep in the abdomen, and early symptoms, such as back pain, fatigue, weight loss or digestive discomfort, are vague and often mistaken for other, less serious conditions,' Dr. Diane Simeone, director of Moores Cancer Center at UC San Diego Health, told The Post. Jaundice — the yellowing of the skin and the whites of the eyes — is a clearer sign of pancreatic cancer. Simeone highlights why many patients get this sneaky symptom — and why screening is so important. Advertisement What is jaundice? Jaundice occurs when the blood has excess bilirubin, a yellowish substance that's produced when the body breaks down old red blood cells. The liver is most responsible for eliminating bilirubin. 4 Jaundice — the yellowing of the skin and the whites of the eyes — is a visible sign of pancreatic cancer. New Africa – Advertisement A tumor blocking the bile ducts or affecting the liver's function can prevent the proper processing of bilirubin, causing the pigment to accumulate. The yellowing of the whites of the eyes is often the first noticeable sign — the skin and the inside of the mouth may turn yellow as well. Jaundice can also cause dark urine, pale poop and sometimes itchy skin and stomach pain. Advertisement 'The excess bilirubin is excreted through the kidneys, darkening the urine and preventing it from reaching the intestines, which leads to pale stools,' Simeone explained. 'It can also cause itching because the bile acids that are not being excreted normally accumulate in the skin and stimulate nerve endings.' Stomach pain can be felt from a tumor obstructing the bile duct. Jaundice can signal pancreatic cancer — and what else? Elevated levels of bilirubin often indicate liver troubles. Hepatitis (inflammation of the liver), cirrhosis (scarring of the liver) and liver cancer can be culprits. 4 Jaundice can indicate problems with the liver. Here, a doctor shows the anatomy of the liver to a patient. Peakstock – Other suspects include gallstones in the bile duct, certain blood disorders, viral or bacterial infections, some medications and genetic conditions. Newborns can experience jaundice because their liver isn't fully developed. With pancreatic cancer, jaundice is a common symptom when the tumor is in the head of the pancreas, blocking the common bile duct. How is pancreatic cancer diagnosed? Advertisement Pancreatic cancer screening is generally recommended for those with a family history of the disease, genetic mutations linked to a higher risk and pancreatic conditions like chronic pancreatitis. MRIs, CT scans and endoscopic ultrasounds visualize the pancreas and surrounding areas to see if there's a tumor. If one is detected, a tissue or cell sample is taken to determine if it's cancerous and, if so, the stage of the cancer. 'There are certain blood tests that help in the diagnosis, such as liver function tests, complete blood counts and tumor markers like CA 19-9,' Simeone said, referring to Cancer Antigen 19-9, a protein that can be released by pancreatic cancer cells into the bloodstream. Advertisement 'The mission of PRECEDE is to help identify an early detection biomarker, such as a blood test that can discover the cancer at the earliest possible stage.' 4 Surgeons operate on a pancreatic cancer patient in France on June 7, 2019. Surgery is one of the potential treatment options for the disease. AFP via Getty Images Simeone is the founding director of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, which is studying over 9,500 high-risk individuals to improve early detection of pancreatic cancer. The goal is to increase the five-year survival rate from 13% to 50% through collaborative research, standardization of screening protocols and development of early detection tools. How is pancreatic cancer treated? Advertisement Depending on when the cancer is caught, treatment options may include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy and palliative care. 'Surgical resection [to remove the tumor] is typically only an effective option before the cancer has spread,' Simeone said. 'This is precisely why early detection is so important and PRECEDE's primary mission and focus.'
